Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013 American Academy of Neurology Annual Meeting

  Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013
  American Academy of Neurology Annual Meeting


Business Wire

JERUSALEM -- March 14, 2013

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that 15
abstracts highlighting study results for Parkinson’s disease (PD) and
relapsing-remitting multiple sclerosis (RRMS) will be presented during the
65^th American Academy of Neurology (AAN) annual meeting in San Diego, Calif.,
March 16-23, 2013. New data for AZILECT^® (rasagiline tablets), an MAO-B
inhibitor for the treatment of PD, will be presented as part of the meeting’s
Emerging Science program (formerly known as Late-Breaking Science) on
Wednesday, March 20^th at 5:45pm PST.

“We are pleased with the variety of topics and quality of research results
that will be presented at AAN this year,” said Dr. Michael Hayden, President
of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries
Ltd. “Teva’s legacy in CNS is grounded in our commitment to ongoing
collaboration with academia, medical institutions, and patient advocacy groups
to find innovative solutions for patients who live with chronic and
debilitating diseases, such as RRMS and Parkinson’s disease.”

Featured presentations include:

  *Results from a Phase IV clinical study evaluating AZILECT^® as Add on to
    Dopamine Agonists in the Treatment of Parkinson's disease (ANDANTE).
  *Findings from the first year of follow-up in the Therapy Optimization in
    Multiple Sclerosis (TOP MS) study, the largest prospective Phase IV study
    conducted in RRMS, providing insight into the impact of adherence to
    therapy, as well as data demonstrating that more patients on COPAXONE^®
    (glatiramer acetate) persisted with treatment than those on beta
    interferon (IFN).
  *Results from the Phase III ALLEGRO study in RRMS at 36 months, comparing
    the progression of disability and safety of patients treated with
    laquinimod for three years (Early-Start) and in patients originally
    treated with placebo in the double-blind (DB) phase and switched to
    laquinimod treatment (Delayed-Start) in the open-label (OL) phase of the
    ALLEGRO trial.

Platform Presentation/Poster Session Details:


  *[Emerging Science Platform Session - 006] A placebo controlled,
    randomized, double-blind study to assess the safety and clinical benefit
    of rasagiline as an add-on therapy to dopamine agonist monotherapy in
    early Parkinson’s disease (PD): The ANDANTE study [Wednesday, March 20,
    2013 5:45PM] Robert A. Hauser, MD, MBA; Dee Silver, MD, Azhar Choudhry,
    MD, MBA, Stuart Isaacson MD
  *[P02.082] Novel Exploratory Study To Examine the Effect of Rasagiline on
    Tissue Injury in the Substantia Nigra Using Multi-Modal 3T Advanced MRI
    Techniques in Patients with Parkinson's Disease [Session P02, Tuesday,
    March 19, 2013 7:30 AM] Edwin George, Detroit, MI, Shana Krstevska,
    Detroit, MI, Fen Bao, Detroit, MI, Veronica Gorden, Detroit, MI, Carla
    Santiago Martinez, Detroit, MI, Natalya Shneyder, Detroit, MI, Christina
    Caon, Detroit, MI, Omar Khan, Detroit, MI


  *[P01.193] MS Therapy Adherence and Relapse Risk [Session P06,
    Monday, March 18, 2013 2:00 PM] Bruce Cohen, Chicago, IL, Thomas Leist,
    Philadelphia, PA, Patricia Coyle, Stony Brook, NY, Howard Zwibel, Coral
    Gables, FL, Clyde Markowitz, Philadelphia, PA, Mark Tullman, Saint Louis,
  *[P03.200] MS Therapy Persistence and Treatment Patterns [Session P03,
    Tuesday, March 19, 2013 2:00 PM] Clyde Markowitz, Philadelphia, PA,
    Patricia Coyle, Stony Brook, NY, Thomas Leist, Philadelphia, PA, Bruce
    Cohen, Chicago, IL, Howard Zwibel, Coral Gables, FL, Mark Tullman, Saint
    Louis, MO


  *[S41.004] Comparison of Early and Delayed Oral Laquinimod in Patients with
    Relapsing-Remitting Multiple Sclerosis: Effects on Disability Progression
    at 36 months in the ALLEGRO Trial [Session S41, Thursday, March 21, 2013
    12:45 PM] Giancarlo Comi, MD, Department of Neurology and Institute of
    Experimental Neurology Università et al.
  *[P05.197] Therapeutic Laquinimod Treatment Restores Axon Myelination,
    Callosal Conduction and Motor Deficit in a Chronic Mouse Model of Multiple
    Sclerosis [Session P05, Wednesday March 20, 2013 2:00 PM EST] Spencer
    Moore, Los Angeles, CA, Gemmy Hannsun, Los Angeles, CA, Jane Yoon, Los
    Angeles, CA, Rhusheet Patel, Los Angeles, Timothy Yoo, Los Angeles, CA,
    Anna Khalaj, Los Angeles, CA, Seema Tiwari-Woodruff, Los Angeles, CA
  *[P06.126] Laquinimod Treatment Reverses Cortical and Hippocampus Pathology
    Due to Inflammatory Demyelination in a Chronic Mouse Model of Multiple
    Sclerosis [Session P06, Thursday, March 21, 2013 7:30 AM] Anna Khalaj, Duc
    Nguyen, Juspreet Nakai, JaeHee Yoon, Taryn McLaughlin, Daniel Ichwan, and
    Seema Tiwari-Woodruff Department of Neurology, UCLA School of Medicine,
    Los Angeles, USA

About Azilect^®

AZILECT^® (rasagiline tablets) is indicated for the treatment of the signs and
symptoms of Parkinson's disease (PD) both as initial therapy alone and to be
added to levodopa later in the disease.

Patients should not take AZILECT^® if they are taking meperidine, tramadol,
methadone, propoxyphene, dextromethorphan, St. John’s wort, cyclobenzaprine,
or other monoamine oxidase inhibitors (MAOIs), as it could result in a serious
reaction. Patients should inform their physician if they are taking, or
planning to take, any prescription or over-the-counter drugs, especially
antidepressants and ciprofloxacin. Patients with moderate to severe liver
disease should not take AZILECT^®. Patients should not exceed a dose of 1 mg
per day of AZILECT^® in order to prevent a possibly dangerous increase in
blood pressure.

Side effects seen with AZILECT^® alone are flu syndrome, joint pain,
depression, and indigestion; and when taken with levodopa are uncontrolled
movements (dyskinesia), accidental injury, weight loss, low blood pressure
when standing, vomiting, anorexia, joint pain, abdominal pain, nausea,
constipation, dry mouth, rash, abnormal dreams, and fall.

See additional important information at For
hardcopy releases, please see enclosed full prescribing information.

AZILECT^® is currently available in more than 40 countries worldwide,
including the U.S., Canada, Israel, Mexico, and all EU countries. Teva has a
long-term agreement for the joint development and marketing of AZILECT^® in
Europe and some additional markets with H. Lundbeck A/S. In North America,
AZILECT^® is marketed by Teva's wholly-owned subsidiary, Teva Neuroscience,
Inc. (

About Copaxone^®

Copaxone^® (glatiramer acetate injection) is indicated for the reduction of
the frequency of relapses in relapsing-remitting multiple sclerosis, including
patients who have experienced a first clinical episode and have MRI features
consistent with multiple sclerosis.

The most common side effects of COPAXONE® are redness, pain, swelling,
itching, or a lump at the site of injection, flushing, rash, shortness of
breath, and chest pain.

See additional important information at: For
hardcopy releases, please see enclosed full prescribing information.

COPAXONE® is now approved in more than 50 countries worldwide, including the
United States, Russia, Canada, Mexico, Australia, Israel, and all European

About Laquinimod

Laquinimod is an oral, once-daily CNS-active immunomodulator with a novel
mechanism of action being developed for the treatment of MS. In animal models,
laquinimod crosses the blood-brain barrier to potentially have a direct effect
on the neurodegenerative processes of MS. The global Phase III clinical
development program evaluating oral laquinimod in MS includes two pivotal
studies, ALLEGRO and BRAVO. A third Phase III laquinimod trial, CONCERTO, is
evaluating two doses of the investigational product (0.6mg and 1.2mg) in
approximately 1,800 patients for up to 24 months. The primary outcome measure
will be confirmed disability progression as measured by the Expanded
Disability Status Scale (EDSS). In addition to the MS clinical studies,
laquinimod is currently in Phase II of development for Crohn's disease and

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $20.3 billion in net revenues in 2012.

Teva's Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995:

This release contains forward-looking statements, which express the current
beliefs and expectations of management. Such statements are based on
management’s current beliefs and expectations and involve a number of known
and unknown risks and uncertainties that could cause our future results,
performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements, including statements relating to the results of the GALA phase III
trial and the potential efficacy or future market or marketability of
glatiramer acetate 40 mg/1 ml. Following further analysis, Teva's
interpretation of the results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release as there can be no
guarantee that the results from the phase III trial discussed in this press
release will be confirmed upon full analysis of the results of the trial and
additional information relating to the safety, efficacy or tolerability of
glatiramer acetate 40 mg/1 ml may be discovered upon further analysis of data
from the phase III trial. Even if the results described in this release are
confirmed upon full analysis of the GALA study, we cannot guarantee that
glatiramer acetate 40 mg/1 ml will be approved for marketing in a timely
manner, if at all, by regulatory authorities in the EU or in the U.S.
Important factors that could cause or contribute to such differences include
risks relating to: our ability to develop and commercialize additional
pharmaceutical products, competition for our innovative products, especially
Copaxone® (including competition from innovative orally-administered
alternatives, as well as from potential generic equivalents), competition for
our generic products (including from other pharmaceutical companies and as a
result of increased governmental pricing pressures), competition for our
specialty pharmaceutical businesses, our ability to achieve expected results
through our innovative R&D efforts, the effectiveness of our patents and other
protections for innovative products, decreasing opportunities to obtain U.S.
market exclusivity for significant new generic products, our ability to
identify, consummate and successfully integrate acquisitions (including the
acquisition of Cephalon), the effects of increased leverage as a result of the
acquisition of Cephalon, the extent to which any manufacturing or quality
control problems damage our reputation for high quality production and require
costly remediation, our potential exposure to product liability claims to the
extent not covered by insurance, increased government scrutiny in both the
U.S. and Europe of our agreements with brand companies, potential liability
for sales of generic products prior to a final resolution of outstanding
patent litigation, including that relating to the generic version of
Protonix®, our exposure to currency fluctuations and restrictions as well as
credit risks, the effects of reforms in healthcare regulation and
pharmaceutical pricing and reimbursement, any failures to comply with complex
Medicare and Medicaid reporting and payment obligations, governmental
investigations into sales and marketing practices (particularly for our
specialty pharmaceutical products), uncertainties surrounding the legislative
and regulatory pathway for the registration and approval of
biotechnology-based products, adverse effects of political or economical
instability, major hostilities or acts of terrorism on our significant
worldwide operations, interruptions in our supply chain or problems with our
information technology systems that adversely affect our complex manufacturing
processes, any failure to retain key personnel (including Cephalon employees)
or to attract additional executive and managerial talent, the impact of
continuing consolidation of our distributors and customers, variations in
patent laws that may adversely affect our ability to manufacture our products
in the most efficient manner, potentially significant impairments of
intangible assets and goodwill, potential increases in tax liabilities, the
termination or expiration of governmental programs or tax benefits,
environmental risks and other factors that are discussed in our Annual Report
on Form 20-F for the year ended December 31, 2012 and in our other filings
with the U.S. Securities and Exchange Commission. Forward-looking statements
speak only as of the date on which they are made and the Company undertakes no
obligation to update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise.


Teva Pharmaceutical Industries Ltd.
Kevin C. Mannix
United States
Kristen Frank
United States
Tomer Amitai
972 (3) 926-7656
Hadar Vismunski-Weinberg
972 (3) 926-7687
Denise Bradley
United States
Press spacebar to pause and continue. Press esc to stop.